MedTrace Logo

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

NCT03832179 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-09-12

No results posted yet for this study

Summary

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab

DRUG

Ranibizumab

Ranibizumab

DRUG

Aflibercept

Aflibercept

DRUG

Ozurdex

Ozurdex

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Bay Area Retina Associates

    lead OTHER

Principal Investigators

  • Caesar Luo, MD · Physician

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2023-09-01
Completion
2024-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03832179 on ClinicalTrials.gov